Skip to main content
Top
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma

Authors: Xinghua Zhu, Yaxun Wu, Xiaobing Miao, Chunsun Li, Haibing Yin, Shuyun Yang, Xiaoyun Lu, Yushan Liu, Yali Chen, Rong Shen, Xudong Chen, Song He

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Dysregulation of TRIM44 has been reported to be involved in tumorigenesis, but its role in hepatocellular carcinoma (HCC) remains unclear. In the present study, we investigated the clinicopathological and biological significance of TRIM44 in HCC. We found that TRIM44 mRNA and protein expression was upregulated in HCC compared with matched normal tissues. Intriguingly, we also found that TRIM44 expression was significantly correlated with tumor size (P < 0.001), vascular invasion (P < 0.001), intrahepatic metastasis (P < 0.001), distant metastasis (P < 0.001), and Ki-67 expression (P < 0.001). Kaplan-Meier analysis showed that high TRIM44 staining was significantly correlated with shorter overall survival (P < 0.001). TRIM44 was an independent predictor of overall survival in patients with HCC. Furthermore, we found that ectopic expression of TRIM44 could promote cell proliferation via accelerating the G1/S-phase transition in HCC. Moreover, overexpression of TRIM44 could enhance the invasive and migratory capacity of HCC cells. Meanwhile, we found that high expression of TRIM44 could enhance resistance of HCC cells to doxorubicin via accelerating NF-κB activation. In conclusion, our results suggest that TRIM44 may be a novel prognostic indicator and potential therapeutic target of HCC.
Literature
1.
go back to reference Li XP, Yang XY, et al. Co-expression of CXCL8 and HIF-1alpha is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget. 2015;6(26):22880–9.CrossRefPubMedPubMedCentral Li XP, Yang XY, et al. Co-expression of CXCL8 and HIF-1alpha is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget. 2015;6(26):22880–9.CrossRefPubMedPubMedCentral
2.
go back to reference Zhu G, Shi W, et al. HES5 promotes cell proliferation and invasion through activation of STAT3 and predicts poor survival in hepatocellular carcinoma. Exp Mol Pathol. 2015;99(3):474–84.CrossRefPubMed Zhu G, Shi W, et al. HES5 promotes cell proliferation and invasion through activation of STAT3 and predicts poor survival in hepatocellular carcinoma. Exp Mol Pathol. 2015;99(3):474–84.CrossRefPubMed
3.
go back to reference Zhang S, Shi W, et al. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma. Mol Cell Biochem. 2015;410(1–2):1–9.CrossRefPubMed Zhang S, Shi W, et al. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma. Mol Cell Biochem. 2015;410(1–2):1–9.CrossRefPubMed
5.
go back to reference Ozato K, Shin DM, et al. TRIM family proteins and their emerging roles in innate immunity. Nature reviews. Immunology. 2008;8(11):849–60.PubMedPubMedCentral Ozato K, Shin DM, et al. TRIM family proteins and their emerging roles in innate immunity. Nature reviews. Immunology. 2008;8(11):849–60.PubMedPubMedCentral
6.
go back to reference Hatakeyama STRIM. Proteins and cancer. Nature reviews. Cancer. 2011;11(11):792–804.PubMed Hatakeyama STRIM. Proteins and cancer. Nature reviews. Cancer. 2011;11(11):792–804.PubMed
7.
go back to reference Ong CA, Shannon NB, et al. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014;106(5). Ong CA, Shannon NB, et al. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. 2014;106(5).
8.
go back to reference Urano T, Usui T, et al. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochem Biophys Res Commun. 2009;383(2):263–8.CrossRefPubMed Urano T, Usui T, et al. TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochem Biophys Res Commun. 2009;383(2):263–8.CrossRefPubMed
9.
go back to reference Kashimoto K, Komatsu S, et al. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci. 2012;103(11):2021–6.CrossRefPubMed Kashimoto K, Komatsu S, et al. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci. 2012;103(11):2021–6.CrossRefPubMed
10.
go back to reference Peters CJ, Rees JR, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139(6):1995–2004 e1915.CrossRefPubMed Peters CJ, Rees JR, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139(6):1995–2004 e1915.CrossRefPubMed
11.
go back to reference Luo Q, Lin H, et al. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-kappaB signaling pathway. Int J Clin Oncol. 2015;20(3):508–17.CrossRefPubMed Luo Q, Lin H, et al. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-kappaB signaling pathway. Int J Clin Oncol. 2015;20(3):508–17.CrossRefPubMed
12.
go back to reference Xing Y, Meng Q, et al. TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget. 2016;7:30479–91.PubMedPubMedCentral Xing Y, Meng Q, et al. TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget. 2016;7:30479–91.PubMedPubMedCentral
13.
go back to reference Ranger GS, Thomas V, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004;24(4):2349–51.PubMed Ranger GS, Thomas V, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004;24(4):2349–51.PubMed
14.
go back to reference You B, Cao X, et al. Clinical and biological significance of HAX-1 overexpression in nasopharyngeal carcinoma. Oncotarget. 2016;7:12505–24.PubMedPubMedCentral You B, Cao X, et al. Clinical and biological significance of HAX-1 overexpression in nasopharyngeal carcinoma. Oncotarget. 2016;7:12505–24.PubMedPubMedCentral
15.
go back to reference Wan C, Gong C, et al. Beta2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Cancer Lett. 2016;373(1):67–76.CrossRefPubMed Wan C, Gong C, et al. Beta2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Cancer Lett. 2016;373(1):67–76.CrossRefPubMed
16.
go back to reference Hang Q, Fei M, et al. Expression of Spy1 protein in human non-Hodgkin’s lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 2012;29(5):3504–14.CrossRefPubMed Hang Q, Fei M, et al. Expression of Spy1 protein in human non-Hodgkin’s lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 2012;29(5):3504–14.CrossRefPubMed
17.
go back to reference Tao T, Cheng C, et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell. 2012;23(14):2635–44.CrossRefPubMedPubMedCentral Tao T, Cheng C, et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell. 2012;23(14):2635–44.CrossRefPubMedPubMedCentral
18.
go back to reference Connor KM, Hempel N, et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res. 2007;67(21):10260–7.CrossRefPubMed Connor KM, Hempel N, et al. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res. 2007;67(21):10260–7.CrossRefPubMed
19.
go back to reference Zhang J, Zhu J, et al. Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015;36(9):6701–14.CrossRef Zhang J, Zhu J, et al. Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2015;36(9):6701–14.CrossRef
20.
go back to reference Kong D, Li Y, et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers. 2011;3(1):716–29.CrossRefPubMedPubMedCentral Kong D, Li Y, et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers. 2011;3(1):716–29.CrossRefPubMedPubMedCentral
21.
go back to reference Zhou Y, Liang C, et al. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via FOXO3a activation. Oncotarget. 2015;6(12):10350–65.CrossRefPubMedPubMedCentral Zhou Y, Liang C, et al. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via FOXO3a activation. Oncotarget. 2015;6(12):10350–65.CrossRefPubMedPubMedCentral
22.
go back to reference Bentires-Alj M, Barbu V, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90–7.CrossRefPubMed Bentires-Alj M, Barbu V, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90–7.CrossRefPubMed
23.
go back to reference Lai YJ, Lin VT, et al. The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Mol Cell Biol. 2010;30(23):5582–96.CrossRefPubMedPubMedCentral Lai YJ, Lin VT, et al. The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Mol Cell Biol. 2010;30(23):5582–96.CrossRefPubMedPubMedCentral
24.
go back to reference Lin MT, Chang CC, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem. 2004;279(23):24015–23.CrossRefPubMed Lin MT, Chang CC, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem. 2004;279(23):24015–23.CrossRefPubMed
25.
go back to reference Herquel B, Ouararhni K, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2011;108(20):8212–7.CrossRefPubMedPubMedCentral Herquel B, Ouararhni K, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2011;108(20):8212–7.CrossRefPubMedPubMedCentral
26.
go back to reference Chao J, Zhang XF, et al. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014;31(8):102.CrossRefPubMed Chao J, Zhang XF, et al. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014;31(8):102.CrossRefPubMed
27.
go back to reference Li L, Dong L, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion. Int J Oncol. 2016;48(4):1639–49.PubMed Li L, Dong L, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion. Int J Oncol. 2016;48(4):1639–49.PubMed
28.
go back to reference Wang Y, He D, et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun. 2015;463(3):458–65.CrossRefPubMed Wang Y, He D, et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun. 2015;463(3):458–65.CrossRefPubMed
29.
go back to reference Li Z, Na X, et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2002;277(7):4656–62.CrossRefPubMed Li Z, Na X, et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2002;277(7):4656–62.CrossRefPubMed
30.
go back to reference Li Z, Wang D, et al. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun. 2002;294(3):700–9.CrossRefPubMed Li Z, Wang D, et al. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun. 2002;294(3):700–9.CrossRefPubMed
31.
Metadata
Title
High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma
Authors
Xinghua Zhu
Yaxun Wu
Xiaobing Miao
Chunsun Li
Haibing Yin
Shuyun Yang
Xiaoyun Lu
Yushan Liu
Yali Chen
Rong Shen
Xudong Chen
Song He
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5316-3

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine